US 12,259,381 B2
Methods and compositions for removing biotin interference from assays using molecular traps
Tie Wei, Wilmington, DE (US); Zhu Teng, Garnet Valley, PA (US); and Izak Bahar, Hockessin, DE (US)
Assigned to Siemens Healthcare Diagnostics Inc., Tarrytown, NY (US)
Appl. No. 17/250,609
Filed by Siemens Healthcare Diagnostics Inc., Tarrytown, NY (US)
PCT Filed Sep. 19, 2019, PCT No. PCT/US2019/051867
§ 371(c)(1), (2) Date Feb. 10, 2021,
PCT Pub. No. WO2020/068541, PCT Pub. Date Apr. 2, 2020.
Claims priority of provisional application 62/735,911, filed on Sep. 25, 2018.
Prior Publication US 2021/0311031 A1, Oct. 7, 2021
Int. Cl. G01N 33/53 (2006.01); G01N 33/566 (2006.01)
CPC G01N 33/5306 (2013.01) [G01N 33/566 (2013.01); G01N 2400/18 (2013.01)] 8 Claims
OG exemplary drawing
 
1. A molecular trap to reduce free-hapten interference in an assay, wherein the assay detects a hapten-conjugate that comprises the hapten, and wherein the free-hapten is free-biotin or free-fluorescein, the molecular trap comprising:
a molecular structure that selectively binds to free-hapten, wherein the molecular structure is soluble in an assay solution, the molecular structure comprising:
a modified specific binding partner (sbp) to the free-hapten, wherein the modified sbp to free-biotin is selected from a modified avidin, a modified streptavidin, or a modified traptavidin, and wherein the modified sbp to free-fluorescein comprises a modified anti-fluorescein, wherein the modified sbp is modified by the attachment of one or more of dextran aldehyde, amino dextran, or bovine serum albumin thereto, and wherein the modification to the sbp prevents the hapten-conjugate detected by the assay from binding to the modified sbp; and
a coating comprising a hydrophobic moiety, wherein the hydrophobic moiety is sulfo-N-hydroxy succinimide acetate.